Recent News

• 05.06.2026 - ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.04.2026 - ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
• 04.29.2026 - ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
• 03.27.2026 - ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• 03.25.2026 - ADMA Biologics Addresses Misleading Short-Seller Report

Recent Filings

• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2026 - 8-K Current report
• 05.04.2026 - 8-K Current report
• 05.04.2026 - EX-99.1 EX-99.1
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.15.2026 - DEF 14A Other definitive proxy statements
• 04.15.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.15.2026 - ARS Annual Report to Security Holders
• 04.03.2026 - 4 Statement of changes in beneficial ownership of securities